Results 1 to 10 of about 54,917 (299)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study [PDF]

Frontiers in Cardiovascular Medicine, 2022
BackgroundSodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM).
Arturo Cesaro, Arturo Cesaro, Felice Gragnano, Felice Gragnano, Pasquale Paolisso, Pasquale Paolisso, Luca Bergamaschi, Luca Bergamaschi, Emanuele Gallinoro, Emanuele Gallinoro, Celestino Sardu, Niya Mileva, Alberto Foà, Alberto Foà, Matteo Armillotta, Matteo Armillotta, Angelo Sansonetti, Angelo Sansonetti, Sara Amicone, Sara Amicone, Andrea Impellizzeri, Andrea Impellizzeri, Giuseppe Esposito, Giuseppe Esposito, Nuccia Morici, Jacopo Andrea Oreglia, Gianni Casella, Ciro Mauro, Dobrin Vassilev, Nazzareno Galie, Nazzareno Galie, Gaetano Santulli, Gaetano Santulli, Gaetano Santulli, Carmine Pizzi, Carmine Pizzi, Emanuele Barbato, Emanuele Barbato, Paolo Calabrò, Paolo Calabrò, Raffaele Marfella, Raffaele Marfella   +41 more
doaj   +2 more sources

Gliflozins position update in the treatment algorithms for patients with type 2 diabetes mellitus and chronic kidney disease: new pathogenetic mechanisms and data from subanalyses of the large randomised control trails

Сахарный диабет, 2022
The series of the cardiovascular outcome trails have demonstrated the nephroprotective properties of the gliflozins. Canagliflozin in the CREDENCE, which was the first study with a primary focus on the evaluation of the nephroprotective properties of ...
O. Y. Sukhareva, Z. T. Zuraeva, M. S. Shamhalova   +2 more
doaj   +1 more source

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis [PDF]

Journal of Nephropathology, 2023
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder ...
Mobin Mohammadtabar, Alireza Fazeli, Najmeh Parsai, Zahra Aboulfathiyarmohammadyar, Erfan Shafiei, Mohamad Khaledi, Elahe Zaremoghadam, Ali Rahnama Sisakht, Saeid Mohammadi, Hossein Mardanparvar   +9 more
doaj   +1 more source

SGLT2 Inhibition in Acute Myocardial Infarction—A Comprehensive Review

Reviews in Cardiovascular Medicine, 2023
In heart failure as well as in chronic kidney disease sodium-glucose cotransporter 2 (SGLT2) inhibitors have changed the landscape of medical therapy. Originally developed for use in diabetes, an unforeseen cardiovascular benefit extended SGLT2 inhibitor
Martin Benedikt, Ewald Kolesnik, Harald Sourij, Dirk von Lewinski   +3 more
doaj   +1 more source

Novel Mutations and Genetic Characterization in Korean Patients with Familial Renal Glucosuria [PDF]

Childhood Kidney Diseases, 2018
Purpose Familial renal glucosuria (FRG, OMIM #233100) is a rare but relatively benign genetic condition characterized by persistent isolated glucosuria with a normal blood glucose level.
Weon Kyung Lee, Seung Hwan Oh, Woo Yeong Chung   +2 more
doaj   +1 more source

Cardiology update - The first quarter

Journal of the Practice of Cardiovascular Sciences, 2019
The first round of this year covers a lot about dual-antiplatelet therapy duration after stent placement, coronary angiography after a cardiac arrest, transcatheter aortic valve replacement indications in low-risk patients, sodium–glucose cotransporter 2
Satyavir Yadav, Faraz Ahmed Farooqui, Swati Singh   +2 more
doaj   +1 more source

Dapagliflozin in patients with chronic kidney disease: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled multicenter trials [PDF]

Journal of Nephropathology
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce the mortality rate, hospitalization, and cardiac morbidity in diabetic patients. However, their safety in chronic kidney disease (CKD) individuals is still debatable.
Hamidreza Khodabandeh, Hanieh Molaee, Ladan Ghashghaie, Mohammad Reza Farnia, Soleyman Alivand, Faraz Zandiyeh, Farshad Gharebakhshi, Elham Rashidi, Nahid Mir   +8 more
doaj   +1 more source

Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients [PDF]

Journal of Medical Biochemistry, 2020
Background: Gluconeogenesis and renal glucose excretion in kidneys both play an important role in glucose homeostasis. Sodium-glucose cotransporter (SGLT2), coded by the SLC5A2 gene is responsible for reabsorption up to 99% of the filtered glucose in ...
Klen Jasna, Goričar Katja, Dolžan Vita
doaj  

SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma

Cell Death and Disease, 2022
SGLT2 (sodium-glucose cotransporter 2) is an important mediator of epithelial glucose transport and has been reported that SGLT2, robustly and diffusely expressed in malignant cancer cells, was overexpressed in various tumors, and inhibiting the SGLT2 ...
Wei Wu, Zhenhao Zhang, Doudou Jing, Xin Huang, Dianyun Ren, Zengwu Shao, Zhicai Zhang   +6 more
doaj   +1 more source

The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study

Diabetes & Vascular Disease Research, 2022
Background The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor and incident dementia remains unclear. This study aimed to evaluate the risk of incident dementia with the use of SGLT2 inhibitor.
Wun-Zhih Siao, Tsung-Kun Lin, Jing-Yang Huang, Chin-Feng Tsai, Gwo-Ping Jong   +4 more
doaj   +1 more source